Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

31.47 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Peering Into Legend Biotech's Recent Short Interest
Via Benzinga
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
Via Benzinga
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
Looking Into Legend Biotech's Recent Short Interest
Via Benzinga
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
Via Benzinga
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
The Latest Analyst Ratings For Legend Biotech
Via Benzinga
Assessing Legend Biotech: Insights From 15 Financial Analysts
Via Benzinga
Unveiling 18 Analyst Insights On Legend Biotech
Via Benzinga
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
From Legend Biotech USA Inc.
Via GlobeNewswire
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... 
Via Benzinga
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
Via Benzinga
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your... 
Via Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. 
Via Talk Markets
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
Via Benzinga
CPI Data Sparks Rally in Biotech Stocks
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of... 
Via Benzinga
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis 
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product. 
Via Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
From Legend Biotech Corporation
Via Business Wire
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
In the last three months, IBRX outperformed NVDA by over 3x. 
Via Talk Markets
LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.